The impact of HER2-directed targeted therapy on HER2-positive DCIS of the breast

Gary D. Lewis, Waqar Haque, Andrew Farach, Sandra S. Hatch, E. Brian Butler, Polly A. Niravath, Mary R. Schwartz, Elizabeth Bonefas, Bin S. Teh

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Background: In invasive breast cancer, her2 is a well-established negative prognostic factor. however, its significance on the prognosis of ductal carcinoma in situ (DcIs) of the breast is unclear. as a result, the impact of her2-directed therapy on her2-positive DcIs is unknown and is currently the subject of ongoing clinical trials. In this study, we aim to determine the possible impact of her2-directed targeted therapy on survival outcomes for her2-positive DcIs patients. Materials and methods: The National cancer Data Base (NcDB) was used to retrieve patients with biopsy-proven DcIs diagnosed from 2004–2015. patients were divided into two groups based on the adjuvant therapy they received: systemic her2-directed targeted therapy or no systemic therapy. statistics included multivariable logistic regression to determine factors predictive of receiving systemic therapy, Kaplan-Meier analysis to evaluate overall survival (Os), and cox proportional hazards modeling to determine variables associated with Os. results: altogether, 1927 patients met inclusion criteria; 430 (22.3%) received her2-directed targeted therapy; 1497 (77.7%) did not. patients who received her2-directed targeted therapy had a higher 5-year Os compared to patients that did not (97.7% vs. 95.8%, p = 0.043). This survival benefit remained on multivariable analysis. Factors associated with worse Os on multivariable analysis included charlson-Deyo comorbidity score ≥ 2 and no receipt of hormonal therapy. conclusion: In this large study evaluating her2-positive DcIs patients, the receipt of her2-directed targeted therapy was associated with an improvement in Os. The results of currently ongoing clinical trials are needed to confirm this finding.

Original languageEnglish (US)
Pages (from-to)179-187
Number of pages9
JournalReports of Practical Oncology and Radiotherapy
Issue number2
StatePublished - 2021
Externally publishedYes


  • Breast cancer
  • DcIs
  • Her2
  • Molecular status
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'The impact of HER2-directed targeted therapy on HER2-positive DCIS of the breast'. Together they form a unique fingerprint.

Cite this